Background: Although COX-2 inhibitors are known to have adverse effects on myocardial ischemia, the effects
of COX-2 inhibitors on cardiovascular diseases are still controversial. Thus, we hypothesized that COX-2 inhibitors affect
pressure overloaded myocardial hypertrophy.
Methods and Results: To clarify the role, we used meloxicam in a murine transversal aortic banding (TAC) model.
Meloxicam (0.5mg/kg) was given orally twice a day and the mice were sacrificed on day 28 (n=10) after TAC. The drugfree
vehicle was used as control (n=7). Echocardiogram revealed that left ventricular (LV) wall thickness was significantly
decreased in the meloxicam-treated group compared with the control group. Heart per body weight ratio of the
meloxicam-treated group was substantially less than that of the non-treated group. Pathologically, hearts in the meloxicam-
treated group showed significantly less LV wall thickness and area of myocardium than those in the control group.
RT-PCR showed that COX-2 mRNA levels in hearts increased in the non-treated group, while meloxicam treatment suppressed
Conclusion: Meloxicam may be useful for preventing pressure overloaded myocardial hypertrophy.
Keywords: Echocardiogram, echocardiograms, histology, heart, blood pressure, COX-2 inhibitors, meloxicam, myocardial
hypertrophy, mice, nonsteroidal anti-inflammatory drugs, pathology, pressure overload, transverse aortic constriction, pathology,
polymerase chain reaction, wall thickness
Rights & PermissionsPrintExport